{"schema_version":"secwatch.filing_event.v1","accession":"0000059478-23-000025","form_type":"8-K","ticker":"LLY","cik":"0000059478","company_name":"ELI LILLY & Co","filed_at":"2023-02-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.750114+00:00","generated_at":"2026-06-20T02:55:15.896812+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Lilly Q4 2022 EPS $2.14; revenue down 9%; core up 5%; 2023 guidance $7.90-$8.10","bullets":["Q4 2022 revenue $7.30B (-9% YoY); ex-COVID antibodies revenue +5% (+10% constant currency).","Reported EPS $2.14 (+13%); non-GAAP EPS $2.09 (-4%); includes $0.23 acquired IPR&D charges.","Key growth products (Verzenio, Mounjaro, Jardiance, Taltz, Trulicity, etc.) grew 21% to 70% of revenue.","2023 EPS guidance: reported $7.90-$8.10; non-GAAP $8.35-$8.55; mid-teen core revenue growth expected.","Pipeline: FDA approved Jaypirca for MCL; rolling submission tirzepatide in obesity; Jardiance CKD submissions."],"urls":{"canonical":"https://secwatch.observer/filing/0000059478-23-000025","json":"https://secwatch.observer/filing/0000059478-23-000025.json","markdown":"https://secwatch.observer/filing/0000059478-23-000025.md","text":"https://secwatch.observer/filing/0000059478-23-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/59478/000005947823000025/0000059478-23-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/59478/000005947823000025/lly-20230202.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T02:55:15.896812+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9ab6817cb63096d1e40b6c630d50e7eac105f0d0","claim":"ELI LILLY & Co reported financial results for the quarter and year ended December 31, 2022.","evidence_excerpt":"Attached hereto as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated February 2, 2023, announcing the financial results of Eli Lilly and Company for the quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/59478/000005947823000025/0000059478-23-000025-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}